chymosin.final.ST25 SEQUENCE LISTING

<110> Sudershan Biotech <120> Recombinant calf chymosin and a process for producing the same <130> **PCT0602** <140> PCT/IN2004/000074 <141> 2004-03-30 <160> <170> PatentIn version 3.3 <210> 366 <211> <212> PRT calf <213> <400> Met Ala Ser Ile Thr Arg Ile Pro Leu Tyr Lys Gly Lys Ser Leu Arg $1 \hspace{1cm} 5 \hspace{1cm} 10 \hspace{1cm} 15$ Lys Ala Leu Lys Glu His Gly Leu Leu Glu Asp Phe Leu Gln Lys Gln 20 25 30 Gln Tyr Gly Ile Ser Ser Lys Tyr Ser Gly Phe Gly Glu Val Ala Ser 35 40 45 Val Pro Leu Thr Asn Tyr Leu Asp Ser Gln Tyr Phe Gly Lys Ile Tyr 50 60 Leu Gly Thr Pro Pro Gln Glu Phe Thr Val Leu Phe Asp Thr Gly Ser 65 70 75 80 Ser Asp Phe Trp Val Pro Ser Ile Tyr Cys Lys Ser Asn Ala Cys Lys 85 90 95 Asn His Gln Arg Phe Asp Pro Arg Lys Ser Ser Thr Phe Gln Asn Leu 100 105 110 Gly Lys Pro Leu Ser Ile His Tyr Gly Thr Gly Ser Met Gln Gly Ile 115 120 125 Leu Gly Tyr Asp Thr Val Thr Val Ser Asn Ile Val Asp Ile Gln Gln 130 140 Thr Gly Gly Leu Ser Thr Gln Glu Pro Gly Asp Val Phe Thr Tyr Ala 145 150 155 160

Glu Phe Asp Gly Ile Leu Gly Met Ala Tyr Pro Ser Leu Ala Ser Glu

[AMENDED SHEETS]

Page 1

Tyr Ser Ile Pro Val Phe Asp Asn Met Met Asn Arg His Leu Val Ala Gln Asp Leu Phe Ser Val Tyr Met Asp Arg Asn Gly Gln Glu Ser Met 195 200 205 Leu Thr Leu Gly Ala Ile Asp Pro Ser Tyr Tyr Thr Gly Ser Leu His 210 220 Trp Val Pro Val Thr Val Gln Gln Tyr Trp Gln Phe Thr Val Asp Ser 225 230 235 240 Val Thr Ile Ser Gly Val Val Ala Cys Glu Gly Gly Cys Gln Ala 245 250 255 Ile Leu Asp Thr Gly Thr Ser Lys Leu Val Gly Pro Ser Ser Asp Ile 260 265 270 Leu Asn Ile Gln Gln Ala Ile Gly Ala Thr Gln Asn Gln Tyr Asp Glu 275 280 285 Phe Asp Ile Asp Cys Asn Asn Leu Ser Tyr Met Pro Thr Val Val Phe 290 295 300 Glu Ile Asn Gly Lys Met Tyr Pro Leu Thr Pro Ser Ala Tyr Thr Ser 305 310 315 320 Gln Asp Gln Gly Phe Cys Thr Ser Gly Phe Gln Ser Glu Asn His Ser 325 330 335 Gln Lys Trp Ile Leu Trp Asp Val Phe Ile Arg Glu Tyr Tyr Ser Val 340 345 350 Phe Asp Arg Ala Asn Asn Leu Val Gly Leu Ala Lys Ala Ile 355 360 365

<210> 2 <211> 1101 <212> DNA <213> calf

<400> 2
atggctagca tcactaggat ccctctgtac aaaggcaagt ctctgaggaa ggcgctgaag 60
gagcatgggc ttctggagga cttcctgcag aaacagcagt atggcatcag cagcaagtac 120
tccggcttcg gggaggtggc cagcgtgccc ctgaccaact acctggatag tcagtacttt 180

Page 2



				T LIVINIC IN THE	114 L V / V		
gggaag	atct	acctcgggac	cccgccccag	gagttcaccg		cactggctcc	240
tctgac	ttct	gggtaccctc	tatctactgc	aagagcaatg	cctgcaaaaa	ccaccagcgc	300
ttcgac	ccga	gaaagtcgtc	caccttccag	aacctgggca	agcccctgtc	tatccactac	360
gggaca	ggca	gcatgcaggg	catcctgggc	tatgacaccg	tcactgtctc	caacattgtg	420
gacatc	cagc	agacaggagg	cctgagcacc	caggagcccg	gggacgtctt	cacctatgcc	480
gaattc	gacg	ggatcctggg	gatggcctac	ccctcgctcg	cctcagagta	ctcgataccc	540
gtgttt	gaca	acatgatgaa	caggcacctg	gtggcccaag	acctgttctc	ggtttacatg	600
gacagg	aatg	gccaggagag	catgctcacg	ttgggggcca	tcgacccgtc	ctactacaca	660
gggtcc	ctgc	actgggtgcc	cgtgacagtg	cagcagtact	ggcagttcac	tgtggacagt	720
gtcacc	atca	gcggtgtggt	tgtggcctgt	gagggtggct	gtcaggccat	cctggacacg	780
ggcacc	tcca	agctggtcgg	gcccagcagc	gacatcctca	acatccagca	ggccattgga	840
gccaca	caga	accagtacga	tgagtttgac	atcgactgca	acaacctgag	ctacatgccc	900
actgtg	gtct	ttgagatcaa	tggcaaaatg	tacccactga	cccctccgc	ctataccagc	960
caggac	cagg	gcttctgtac	cagtggcttc	cagagtgaaa	atcattccca	gaaatggatc	1020
ctgtgg	gatg	ttttcatccg	agagtattac	agcgtctttg	acagggccaa	caacctcgtg	1080
gggctg	gcca	aagccatctg	a				1101
<210> <211> <212> <213>		ficial Sequ					
<223>	reve	rse primer	for amplifi	cation of p	repro chymo	sin	
<400> tgtggg	3 gaca	gtgaggttct	tggtc				25
<210> <211> <212> <213>		ficial Sequ	ence				
<220> <223>	forward primer for amplification of prepro chymosin						
<400> 4 atgaggtgtc tcgtggtgct actt							
	5 39 DNA Arti	ficial Sequ	ence				
~2.2A							



<223>	forward primer containing Nde I site	
	5 cata tggctagcat cactaggatc cctctgtac	39
<211> <212>	6 34 DNA Artificial Sequence	
<220> <223>	reverse primer containing Hind III site	
– – .	6 Igct tgacagtgag gttcttggtc agcg	34